Table 2 Treatment-related adverse events reported by 10% or more of patients in the safety population
Any grade 1 | Grade ≥ 3 | |
|---|---|---|
Increased ALT | 8 (40%) | 0 |
Increased conjugated bilirubin | 5 (25%) | 0 |
Increased hemobilirubin | 5 (25%) | 0 |
Increased gamma-glutamyltransferase | 4 (20%) | 0 |
Increase AST | 4 (20%) | 0 |
Increased unconjugated bilirubin | 3 (15%) | 0 |
Increased creatine phosphokinase | 3 (15%) | 0 |
Dysgeusia | 8 (40%) | 0 |
Constipation | 6 (30%) | 0 |
Palmar-plantar erythrodysesthesia | 3 (15%) | 0 |
Papulosis | 2 (10%) | 0 |
Hypertension | 5 (25%) | 3 (15%) |